Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-67 in Myelodysplastic Syndrome (MDS)
NCT00956787Phase 2Unknown
- Sponsor
- Arno Therapeutics, Inc.
- Start
- Jun 2009
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of silatecan in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Arno Therapeutics, Inc. Primary endpoint: Efficacy of AR-67 at 16 weeks. Status: unknown.
02
Drugs
silatecan
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00956787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00956787.